Aptinyx Inc.

Aptinyx Inc.

Last activity: 12.08.2022
Categories: LEDMedTechMessangerPlatformProductBioTechBuildingDevelopmentHealthTechInvestment
We are a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system, starting with painful diabetic neuropathy, fibromyalgia, PTSD and Parkinson’s cognitive impairment. We have a proven platform for discovering proprietary compounds that works through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our pipeline of novel clinical candidates to treat indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more about our company or rewarding career opportunities, please visit our website at www.aptinyx.com or follow us on Twitter @Aptinyx
Location: United States, Illinois, Evanston
Employees: 51-200
Total raised: $135M
Founded date: 2015

Investors 13

Show more

Funding Rounds 2

18.12.2017Series B$70MBain Capit...
10.05.2016Series A$65M-

Mentions in press and media 31

12.08.2022Bolt throws a wrench in the pipeline, look­ing to con­serve ...A melt­down in the biotech mar­ket is mak­ing most ex­ecs cau­tious, in­clud­ing Bolt Bio­ther­a­peu...endpts.com...
12.08.2022House pass­es his­toric drug pric­ing re­forms, lin­ing up d...In 2019, Aptinyx’s stock cratered after it reported that its lead candidate failed a diabetic nerve ...endpts.com...
10.11.2021Aptinyx Reports Third Quarter 2021 Financial Results and Rec...Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Completed enrollment in P...marketscre...
16.09.2021Aptinyx : Secures $50 Million Growth Capital Credit Facility...Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative th...marketscre...
10.08.2021Aptinyx : Initiating CEO transition plan—effective January 1...Initiating CEO transition plan-effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume rol...marketscre...
10.03.2019Clinical trials of Allergan’s antidepressant rapastinel fail...The three studies – RAP-MD-01, -02 and -03 – measured change over a three-week period in baseline me...medcitynew...
16.01.2019Aptinyx shares crater as lead drug fails in PhII neu­ro­path...Aptinyx’s ap­proach to mod­u­lat­ing the NM­DA re­cep­tor to treat dis­or­ders of the cen­tral ner­v...endpts.com...
03.12.20185 Startup Trends that Shaped the Midwest in 2018 1. Marketp...2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. J...hpa.vc/5-s...
29.11.20185 startup trends that shaped the Midwest in 2018We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI an...venturebea...
29.11.20185 startup trends that shaped the Midwest in 20182018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. J...venturebea...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In